A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma
about
Epigenetic regulation of insulin-like growth factor axis in hepatocellular carcinomaTargeting the insulin-like growth factor pathway in hepatocellular carcinomaIdentification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profilingDLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survivalDynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis.Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis.Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.Targeted gene suppression by inducing de novo DNA methylation in the gene promoter.The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets.Cell-specific DNA methylation patterns of retina-specific genesCurrent limitations and future opportunities for epigenetic therapies.Epigenetic changes in prostate cancer: implication for diagnosis and treatment.Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequencesOverexpression of the IGF2-mRNA binding protein p62 in transgenic mice induces a steatotic phenotype.Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P3 and IGF2-P4 regulatory sequences.Flipping the epigenetic switchCorrection of aberrant imprinting of IGF2 in human tumors by nuclear transfer-induced epigenetic reprogrammingDisruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis.Aberrant DNA Methylation of Phosphodiesterase [corrected] 4D Alters Airway Smooth Muscle Cell Phenotypes.Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinomaLong noncoding RNA-mediated intrachromosomal interactions promote imprinting at the Kcnq1 locus.Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistanceLoss of insulin-like growth factor II imprinting is a hallmark associated with enhanced chemo/radiotherapy resistance in cancer stem cells.Methylation of a single intronic CpG mediates expression silencing of the PMP24 gene in prostate cancerIGF2 knockdown in two colorectal cancer cell lines decreases survival, adhesion and modulates survival-associated genes.Epigenetic reprogramming reverses the malignant epigenotype of the MMP/TIMP axis genes in tumor cells.The effect of methylated oligonucleotide targeting Ki-67 gene in human 786-0 renal carcinoma cells.Induction of apoptosis of non-small cell lung cancer by a methylated oligonucleotide targeting survivin gene.Identification of novel sense and antisense transcription at the TRPM2 locus in cancer.Binding and penetration of methylated DNA into primary and transformed human cells.Converting Skin Fibroblasts into Hepatic-like Cells by Transient Programming.Overexpression of miR-483-5p/3p cooperate to inhibit mouse liver fibrosis by suppressing the TGF-β stimulated HSCs in transgenic mice.Development of targeted therapy for a broad spectrum of cancers (pancreatic cancer, ovarian cancer, glioblastoma and HCC) mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences.Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequencesHeritable gene repression through the action of a directed DNA methyltransferase at a chromosomal locus.Specific targeting of cytosine methylation to DNA sequences in vivo.IGF2 mRNA binding protein p62/IMP2-2 in hepatocellular carcinoma: antiapoptotic action is independent of IGF2/PI3K signaling.Profiling the molecular difference between Patched- and p53-dependent rhabdomyosarcoma.MiR-615-5p depresses natural killer cells cytotoxicity through repressing IGF-1R in hepatocellular carcinoma patients.Loss of parental-specific methylation at the IGF2 locus in human hepatocellular carcinoma.
P2860
Q26766068-95D5EAE0-3768-4EE7-918F-6B21C90854B2Q27006846-F241695F-1FB3-4C59-B867-C20BC886D949Q28238147-E2EF5861-93E8-4D92-94FB-52DF29C0FEE1Q28242740-885ADA07-7F71-4AFB-8A7C-61ABFFB0FBD2Q31065757-1E5222DB-9E8A-4D24-A91F-C5F9ED0356CDQ33640296-CAB8855C-E393-4089-AB87-84947B9824E6Q33713001-90840AC9-F873-4193-86A8-C956996B4E2DQ34115881-66B7D684-2532-4254-92BA-8BDAD46A8A94Q34182483-366F02CE-AC4E-4F00-85AD-3454288176FBQ34189565-891B6D77-B66B-4598-8279-D51465B40836Q34195077-36F4BA57-0D28-45E7-9C20-05513793089BQ34385658-96578CEF-A2DD-4248-B987-D9F99FC1EDA5Q34467904-F7D092E7-7CFD-4E41-B042-4C86CA996EC5Q34810309-7D646C98-45E9-4FD7-BC84-43CE4F4816F4Q35040696-788ECF44-1026-4085-8DC3-AEA171922A5FQ35098419-FC7A6A62-BCAD-42BB-8293-71477B63F82DQ35130964-D1D901DF-7293-4E99-9896-B12BEDD1BE04Q35197463-6753BF1E-B33A-4895-94EC-031825DEDD80Q36765933-988BC608-F2CE-43D9-9CA9-9407ED061EDDQ37347288-C8F3FCBE-12ED-468A-8AE0-DC0A7C4BF648Q37441308-E09CB647-F3C2-4F4A-8A10-078F249AED7BQ37478653-DDD05AF6-C746-4004-AD95-19366D2DF2CEQ37588289-1ED90956-DBC5-4888-A091-27B44295A891Q38418382-78015F69-CE73-402E-8896-477E95440A9EQ38736986-C70F7557-42C0-4D7C-9186-FB972331F23EQ39084351-00690946-175C-42FE-B48A-1B15E6026399Q39539382-B7A351B2-CB79-4B87-BC75-D9DA9CED02A0Q39749127-40C87C05-53D0-483F-BF2A-6E80E33F86C7Q39924016-D815180F-0C35-4019-9589-B534864F219CQ39932115-E4531F8C-BAD1-4209-83E4-ADBEC5FA6CECQ41030569-1E27813D-2B72-4479-8934-4FE63464D772Q41886234-BD68C28F-AD9A-4760-B032-652EA805099EQ42012571-9440C5A7-DD9D-4526-B585-8B3BC8C71142Q42049338-658A0D4E-02A2-41AD-9173-52F3EFB09743Q42816880-EF07E23F-2321-46CE-A849-011184925ABFQ42942754-B66FD4DD-BC62-45F8-B67F-89820069795FQ46873887-4DFD794F-ED41-4234-90D0-201E98A9A1ACQ48714160-85AF6BE5-8CA1-402E-8138-56C0F8AA0263Q53141065-664FF0F1-91DB-44C7-A2DE-D14F11E1B235Q54745586-AEC40514-FADB-4D83-8535-02C55D581DE2
P2860
A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
A methylated oligonucleotide i ...... el of hepatocellular carcinoma
@en
A methylated oligonucleotide i ...... l of hepatocellular carcinoma.
@nl
type
label
A methylated oligonucleotide i ...... el of hepatocellular carcinoma
@en
A methylated oligonucleotide i ...... l of hepatocellular carcinoma.
@nl
prefLabel
A methylated oligonucleotide i ...... el of hepatocellular carcinoma
@en
A methylated oligonucleotide i ...... l of hepatocellular carcinoma.
@nl
P2093
P2860
P356
P1476
A methylated oligonucleotide i ...... el of hepatocellular carcinoma
@en
P2093
Andrew R Hoffman
Hadas Shiran
Huifan Yan
Mark Daniels
Qingxue Wang
Xiangjun Zhou
Xiaoming Yao
P2860
P304
P356
10.1172/JCI200315109
P407
P577
2003-01-01T00:00:00Z